Trial Profile
Pharmacokinetics of quinupristin/dalfopristin in patients with Gram-Positive bacterial infections
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs Quinupristin/dalfopristin (Primary)
- Indications Gram-positive infections
- Focus Pharmacokinetics
- 26 May 2012 Planned number of patients changed to 75.
- 26 May 2012 New trial record